In response to sponsor requests, MPI Research announces that the theme of its fifth annual educational summit is Advances in Therapeutic Discovery and Drug Development: Combination Products. This event will be held 10-12 October 2010, at the Radisson Plaza Hotel at Kalamazoo Center in Kalamazoo, Michigan. Seating capacity at this summit is limited, so be sure to register early!
Counterfeiting and tamper evidence are some of the biggest threats within the pharmaceutical industry. From UV features to holographic technology and destructible films, the Fasson® range offers solutions to safeguard your products and your patients.
The pharmaceutical industry demands stringent performance levels and dedicated products. Avery Dennison announces two new pharmaceutical adhesives, with low migration properties and excellent mandrel performance.
Achieve a sustainable supplier strategy with the internationally recognised FSC product range from Fasson. Recognised by the World Wildlife Fund and Greenpeace, Fasson FSC paper products will help you fully meet the exacting demands of leading international brands for a sustainable, eco-friendly future.
Beech Tree Labs, Inc., announced that the FDA has approved its IND for a Phase 1/2a clinical evaluation of BTL-TML-HSV, a novel therapeutic agent for treating recurrent oral herpes infections. The study will be a 210 patient, multi-site, placebo-controlled trial and is anticipated to begin later this summer.
Daiichi Sankyo has signed a research and commercial agreement with BioWa, Inc. and Lonza to use their POTELLIGENT® CHOK1SV cell line for the development and production of recombinant antibodies.
The top results of FPS Food and Pharma Systems' Srl research is the worldwide smallest jet mill for early R&D needs.
Multipharma is committed to offering its clients the highest quality standards available and therefore has chosen Movianto as its preferred logistics provider to cope with the increasing demand for the supply of non-IMP's to study sites.
Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim®, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the US. The manufacturing process for Anthim was optimised for full-scale production by Lonza under a separate agreement announced in June 2009. The Anthim manufacturing process uses Lonza’s GS Gene Expression System™.
Innovaro, a comprehensive innovation solutions company, today announced they have signed an ongoing IP services agreement with Core Oncology, Inc., an innovator in the field of radiation oncology, introduced by Verdant Ventures Advisors LLC.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.